DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $99,095,358 | +1.0% | 399,417 | -2.3% | 0.36% | +7.9% |
| Q2 2023 | $98,136,480 | -4.8% | 408,902 | 0.0% | 0.33% | -10.1% |
| Q1 2023 | $103,059,660 | -4.7% | 408,902 | +0.4% | 0.37% | -10.0% |
| Q4 2022 | $108,145,114 | +2.9% | 407,449 | +0.2% | 0.41% | -3.8% |
| Q3 2022 | $105,078,000 | +4.0% | 406,822 | +2.1% | 0.42% | +10.7% |
| Q2 2022 | $101,059,000 | -9.1% | 398,622 | +5.2% | 0.38% | +8.5% |
| Q1 2022 | $111,182,000 | -10.8% | 379,032 | 0.0% | 0.35% | -1.9% |
| Q4 2021 | $124,705,000 | +7.8% | 379,032 | -0.2% | 0.36% | +0.8% |
| Q3 2021 | $115,646,000 | +13.0% | 379,866 | -0.4% | 0.36% | +6.9% |
| Q2 2021 | $102,332,000 | +17.7% | 381,324 | -1.3% | 0.34% | +9.8% |
| Q1 2021 | $86,963,000 | -3.7% | 386,363 | -4.9% | 0.30% | -4.4% |
| Q4 2020 | $90,286,000 | -1.4% | 406,439 | -4.4% | 0.32% | -12.1% |
| Q3 2020 | $91,583,000 | +18.7% | 425,316 | -2.5% | 0.36% | +12.7% |
| Q2 2020 | $77,143,000 | +16.4% | 436,257 | -8.9% | 0.32% | +0.3% |
| Q1 2020 | $66,291,000 | -9.8% | 478,950 | 0.0% | 0.32% | +15.9% |
| Q4 2019 | $73,509,000 | +2.9% | 478,950 | -3.2% | 0.28% | +0.7% |
| Q3 2019 | $71,450,000 | +85.2% | 494,700 | +83.2% | 0.28% | +91.0% |
| Q2 2019 | $38,588,000 | -2.6% | 270,000 | -10.0% | 0.14% | -2.7% |
| Q1 2019 | $39,606,000 | +140.1% | 300,000 | +87.5% | 0.15% | +111.4% |
| Q4 2018 | $16,499,000 | -5.1% | 160,000 | 0.0% | 0.07% | +9.4% |
| Q3 2018 | $17,386,000 | +10.1% | 160,000 | 0.0% | 0.06% | +6.7% |
| Q2 2018 | $15,789,000 | +0.8% | 160,000 | 0.0% | 0.06% | 0.0% |
| Q1 2018 | $15,666,000 | +5.5% | 160,000 | 0.0% | 0.06% | +7.1% |
| Q4 2017 | $14,851,000 | +8.2% | 160,000 | 0.0% | 0.06% | +1.8% |
| Q3 2017 | $13,725,000 | +1.7% | 160,000 | 0.0% | 0.06% | 0.0% |
| Q2 2017 | $13,502,000 | -1.3% | 160,000 | 0.0% | 0.06% | -3.5% |
| Q1 2017 | $13,685,000 | +9.9% | 160,000 | 0.0% | 0.06% | +7.5% |
| Q4 2016 | $12,454,000 | -0.7% | 160,000 | 0.0% | 0.05% | -1.9% |
| Q3 2016 | $12,542,000 | -22.4% | 160,000 | 0.0% | 0.05% | -26.0% |
| Q2 2016 | $16,160,000 | -14.8% | 160,000 | -20.0% | 0.07% | -15.1% |
| Q1 2016 | $18,972,000 | -48.9% | 200,000 | -50.0% | 0.09% | +8.9% |
| Q4 2015 | $37,152,000 | +294.6% | 400,000 | +263.6% | 0.08% | +119.4% |
| Q2 2015 | $9,415,000 | -38.4% | 110,000 | -38.9% | 0.04% | -40.0% |
| Q1 2015 | $15,282,000 | -30.1% | 180,000 | -29.4% | 0.06% | -28.6% |
| Q4 2014 | $21,856,000 | -4.1% | 255,000 | -15.0% | 0.08% | -6.7% |
| Q3 2014 | $22,794,000 | +3.4% | 300,000 | +7.1% | 0.09% | +2.3% |
| Q2 2014 | $22,044,000 | – | 280,000 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |